BioNTech SE (BNTX) Stock Analysis — Fair Value, Risk & Moat Rating
NMS · Healthcare · Biotechnology
Is BioNTech SE a safe investment right now?
BioNTech SE's Altman Z-Score of 7.84 places it in the safe zone. Fair value estimate is not available for this stock. Moat rating: 2.3/5 stars.
Could BioNTech SE go bankrupt? Altman Z-Score analysis
Z-Score of 7.84 is above 3.0, indicating the company is financially healthy by this metric.
- Below 1.8 — Distress Zone (high bankruptcy risk)
- 1.8 to 3.0 — Gray Zone (elevated uncertainty)
- Above 3.0 — Safe Zone (financially healthy)
What drives BNTX's Z-Score?
| Component | Formula | Value | Weight | Contribution |
|---|---|---|---|---|
| A · Working Capital / Total Assets | WC / TA | 0.6369 | 1.2 | 0.76 |
| B · Retained Earnings / Total Assets | RE / TA | 0.8169 | 1.4 | 1.14 |
| C · EBIT / Total Assets | EBIT / TA | -0.0471 | 3.3 | -0.16 |
| D · Market Cap / Total Liabilities | MCap / TL | 9.9346 | 0.6 | 5.96 |
| E · Revenue / Total Assets | Rev / TA | 0.1305 | 1.0 | 0.13 |
How has BNTX's financial health changed over time?
| Year | Z-Score | Zone |
|---|---|---|
| 2022 | 9.81 | Safe |
| 2023 | 8.42 | Safe |
| 2024 | 7.36 | Safe |
| 2025 | 7.84 | Safe |
Source: Calculated from BNTX's latest 10-K filing on SEC EDGAR.
What is BioNTech SE actually worth?
Source: Earnings data from SEC EDGAR filings. Market data via Yahoo Finance.
Does BioNTech SE have a durable competitive advantage?
Moat rating: 2.3/5.
What makes up BNTX's moat score?
ROIC Stability
ROIC variability over the past decade. Score: 2/5.
Gross Margin Trend
Gross margin trajectory over the past decade. Score: 2/5.
Switching Costs
Estimated customer lock-in based on margin level. Score: 3/5.
How stable is BNTX's return on invested capital?
| Year | ROIC | Trend |
|---|---|---|
| 2022 | 60.0% | — |
| 2023 | 5.8% | Declining |
| 2024 | -3.4% | Declining |
| 2025 | -5.3% | Declining |
Source: ROIC calculated from SEC EDGAR filings.
Is BioNTech SE's dividend safe?
BioNTech SE's key financial metrics
| Metric | Latest | 1Y Ago | 3Y Ago | Trend |
|---|---|---|---|---|
| Revenue | $2.9B | $2.8B | $17.3B | Declining |
| Net Income | −$1.1B | −$0.7B | $9.4B | Declining |
| Free Cash Flow | −$0.3B | −$0.2B | $13.2B | Declining |
| Gross Margin | 77.6% | 80.3% | 82.7% | Declining |
Recent events that affect our BNTX analysis
BNTX earnings report scheduled
Upcoming report. Consensus EPS estimate: $-1.91. Revenue estimate: $165.9M.
BNTX analyst consensus: 74% bullish (14 of 19 analysts)
1 Strong Buy, 13 Buy, 4 Hold, 0 Sell, 1 Strong Sell. Consensus target: $130.84 (20.5% upside).
BNTX missed EPS estimates by 30.4%
Reported EPS: $-0.33 vs estimate $-0.25.
BNTX missed EPS estimates by 220.3%
Reported EPS: $-0.12 vs estimate $0.10.
BNTX missed EPS estimates by 13.8%
Reported EPS: $-1.60 vs estimate $-1.41.
BNTX beat EPS estimates by 26.3%
Reported EPS: $-1.73 vs estimate $-2.35.
BNTX beat EPS estimates by 144.4%
Reported EPS: $1.08 vs estimate $0.44.
Common questions about BioNTech SE
What is BioNTech SE stock price today?
BioNTech SE (BNTX) stock price is $108.60 as of the latest market close, traded on the NASDAQ exchange.
What does BioNTech SE do?
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. It offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer.
What is BioNTech SE market cap?
BioNTech SE has a market capitalization of $27.46B, classifying it as a large-cap stock in the Healthcare sector.
What sector and industry is BNTX in?
BioNTech SE operates in the Healthcare sector, specifically within the Biotechnology industry. It trades on the NASDAQ under the ticker symbol BNTX.
Is BNTX stock overvalued or undervalued?
We do not have sufficient earnings data to produce a reliable fair value estimate for BioNTech SE at this time. Stocks without stable earnings history are difficult to value using traditional models.
What is BNTX stock forecast and analyst target price?
Based on 18 Wall Street analysts, the consensus price target for BioNTech SE is $130.84, implying upside of 20.5% from the current price.
- Analyst High Target: $173.60
- Analyst Low Target: $75.42
Note: Analyst targets are shown for reference and are not used in our valuation model.
Is BioNTech SE revenue and earnings growing?
Here are the analyst consensus growth estimates for BioNTech SE:
- Revenue growth (current year est.): -23.1%
- EPS growth (current year est.): -763.0%
- Revenue growth (next year est.): 4.8%
- EPS growth (next year est.): 9.5%
What are BioNTech SE's key financial metrics?
| Metric | Latest | Trend |
|---|---|---|
| Revenue | $2.9B | Declining |
| Net Income | −$1.1B | Declining |
| Free Cash Flow | −$0.3B | Declining |
| Gross Margin | 77.6% | Declining |
What is BNTX's P/E ratio?
The price-to-earnings ratio measures how much investors pay per dollar of earnings:
- Forward P/E (next 12 months est.): -24.7x
How volatile is BNTX stock?
BioNTech SE has a beta of 1.59, meaning it is significantly more volatile than the broader market. A beta above 1.0 indicates higher price swings relative to the S&P 500, while below 1.0 suggests more stability.
How much cash and debt does BioNTech SE have?
BioNTech SE's balance sheet shows:
- Total Cash: $13.74B
- Total Debt: $267.4M
- Net Cash Position: $13.47B
A positive net cash position means the company holds more cash than debt, reducing financial risk.
What is BioNTech SE's free cash flow?
BioNTech SE generated $-1.10B in trailing twelve-month free cash flow (from $456.0M in operating cash flow). Free cash flow represents the cash available for dividends, buybacks, and debt reduction after all capital expenditures.
Does BioNTech SE pay a dividend?
BioNTech SE does not currently pay a regular dividend to shareholders. The company may be reinvesting all profits back into growth, or it may have suspended its dividend.
Is BioNTech SE at risk of going bankrupt?
BioNTech SE's Altman Z-Score is 7.84, placing it in the safe zone (above 3.0) — bankruptcy risk is low. The Z-Score uses five balance sheet ratios to predict bankruptcy probability within two years.
Does BioNTech SE have a durable competitive advantage?
BioNTech SE scores 2.3/5 stars (Weak moat) in our moat analysis:
- ROIC Stability: 2/5
- Gross Margin Trend: 2/5
- Switching Costs: 3/5
A score above 3.5 suggests meaningful pricing power and a defensible market position.
What is BNTX's return on equity (ROE)?
BioNTech SE's return on equity is -5.9%. ROE measures how efficiently a company generates profits from shareholder equity. An ROE above 15% is generally considered strong, while below 10% may signal inefficiency.
How do I buy BNTX stock?
BNTX shares can be purchased through any brokerage account that provides access to the NASDAQ. Common steps:
- Open an account with a broker (e.g., Fidelity, Schwab, Interactive Brokers)
- Search for ticker symbol BNTX
- Place a market or limit order for your desired number of shares
This is not investment advice. Always do your own research before buying any stock.
Is BNTX a value stock or speculative?
FairValueLabs classifies BioNTech SE as Pure Speculation. It lacks the financial stability or valuation margin typically required for value investing. This stock is considered high risk.
Who is the CEO of BioNTech SE?
The current CEO of BioNTech SE is Dr. Ugur Sahin M.D..
What is BNTX's earnings per share (EPS)?
Earnings per share measures the company's profit allocated to each outstanding share:
- Trailing EPS (last 12 months): $-5.54
- Forward EPS (next 12 months est.): $-4.40
- Analyst consensus EPS (this year): $-4.14
- Analyst consensus EPS (next year): $-3.75
Other Healthcare companies analyzed by FairValueLabs
FairValueLabs Disclaimer
All valuations, scores, ratings, and classifications on this page are produced by the FairValueLabs internal valuation system. They do not represent actual market value, guaranteed outcomes, or professional investment advice. These are analytical estimates for educational and research purposes only.
This is not financial advice. All data is sourced from SEC EDGAR public filings. Always consult a qualified financial advisor before making investment decisions.
Last updated: Apr 22, 2026. Data sources: SEC EDGAR (financial statements), Yahoo Finance (market data, analyst consensus). Data may not reflect the most recent quarter.
BNTX analysis methodology: How we calculate fair value, Z-Scores, and moat ratings